Antiproliferative and anti-apoptotic effect of astaxanthin in an oxygen-induced retinopathy mouse model

被引:14
作者
Kucukoduk, Ali [1 ]
Helvacioglu, Fatma [2 ]
Haberal, Nihan [3 ]
Dagdeviren, Attila [2 ]
Bacanli, Didem [4 ]
Yilmaz, Gursel [1 ]
Akkoyun, Imren [1 ]
机构
[1] Baskent Univ, Fac Med, Dept Ophthalmol, 10 Sok,45, TR-06490 Ankara, Turkey
[2] Baskent Univ, Fac Med, Dept Histol & Embryol, Ankara, Turkey
[3] Baskent Univ, Fac Med, Dept Pathol, Ankara, Turkey
[4] Baskent Univ, Fac Med, Breeding Ctr, Ankara, Turkey
来源
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE | 2019年 / 54卷 / 01期
关键词
ENDOTHELIAL GROWTH-FACTOR; REDUCES RETINAL NEOVASCULARIZATION; IN-VITRO; CHOROIDAL NEOVASCULARIZATION; OXIDATIVE STRESS; ANGIOGENESIS; CELLS; VEGF; ACTIVATION; MICE;
D O I
10.1016/j.jcjo.2018.02.017
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To evaluate the impact of intravitreal (IV) and intraperitoneal (IP) astaxanthin (AST) injections on neovascular development (ND), retinal morphology, and apoptotic activity in a C57BL/6J mouse model with hyperoxia-induced retinopathy (HIR). Design: C57BL/6J mouse model. Methods: Two negative control groups (n = 6 each; one of which received IV sterile dimethyl sulfoxide [DMSO]) of C57BL/6J-type mice were exposed to room air. The HIR groups included 36 C57BL/6J-type mice exposed to 75% +/- 2% oxygen from postnatal day (PD) 7 to PD 12. On PD 12, these mice were randomized into 6 groups (n = 6 each): 2 HIR control groups (one of which received IV-DMSO), 2 IV-AST groups (10 and 100 mu g/mL), and 2 IP-AST groups (0.5 and 5 mg/kg). We measured ND by counting neovascular tufts in cross sections and examined histological, ultrastructural changes via light and electron microscopy. Apoptosis was detected using terminal deoxynucleotidyl transferase-mediated nick end-labeling. Results: No ND was detected in the negative control groups. ND levels were not significantly different between high- and low-dose AST for either means of administration. However, ND levels were significantly lower in the AST groups, regardless of delivery, compared to the control groups. The means of delivery (IP versus IV) also yielded significant differences in ND. The incidence of mitochondrial dysmorphology and apoptosis were lower in groups receiving AST. Conclusions: AST seems to suppress ND and has anti-apoptotic activity in the HIR mouse model.
引用
收藏
页码:65 / 74
页数:10
相关论文
共 57 条
[1]   Impact of triamcinolone acetonide on retinal endothelial cells in a retinopathy of prematurity mouse model [J].
Akkoyun, Imren ;
Yilmaz, Gursel ;
Oto, Sibel ;
Kahraman, Burcu ;
Haberal, Nihan ;
Akova, Yonca A. .
ACTA OPHTHALMOLOGICA SCANDINAVICA, 2007, 85 (07) :791-794
[2]   Structural consequences after intravitreal bevacizumab injection without increasing apoptotic cell death in a retinopathy of prematurity mouse model [J].
Akkoyun, Imren ;
Karabay, Gulten ;
Haberal, Nihan ;
Dagdeviren, Attila ;
Yilmaz, Gursel ;
Oto, Sibel ;
Erkanli, Leyla ;
Akova, Yonca A. .
ACTA OPHTHALMOLOGICA, 2012, 90 (06) :564-570
[3]   T2-TrpRS inhibits preretinal neovascularization and enhances physiological vascular regrowth in OIR as assessed by a new method of quantification [J].
Banin, Eyal ;
Dorrell, Michael I. ;
Aguilar, Edith ;
Ritter, Matthew R. ;
Aderman, Christopher M. ;
Smith, Alexandra C. H. ;
Friedlander, Jeffrey ;
Friedlander, Martin .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2006, 47 (05) :2125-2134
[4]   Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity [J].
Beharry, Kay D. ;
Valencia, Gloria B. ;
Lazzaro, Douglas R. ;
Aranda, Jacob V. .
SEMINARS IN PERINATOLOGY, 2016, 40 (03) :189-202
[5]  
Benítez-Bribiesca L, 2000, ANN NY ACAD SCI, V926, P165
[6]  
Benninghof A, 2008, ANATOMIE, V1, P61
[7]   Neovascularization: Ocular Diseases, Animal Models and Therapies [J].
Cai, Xue ;
Sezate, Steven A. ;
McGinnis, James F. .
RETINAL DEGENERATIVE DISEASES, 2012, 723 :245-252
[8]   Molecular pathogenesis of retinal and choroidal vascular diseases [J].
Campochiaro, Peter A. .
PROGRESS IN RETINAL AND EYE RESEARCH, 2015, 49 :67-81
[9]  
Chew BP, 1999, ANTICANCER RES, V19, P1849
[10]  
Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477